Global Mantle Cell Lymphoma Therapeutics Market 2019-2023
SKU ID : TNV-14498956 | Publishing Date : 24-Jul-2019 | No. of pages : 131
Detailed TOC of Global Mantle Cell Lymphoma Therapeutics Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
Market segmentation by product
Comparison by product
Combination therapy - Market size and forecast 2018-2023
Monotherapy - Market size and forecast 2018-2023
Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
Advent of novel therapies
Research grants and funding
Special drug designations
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
Competitive scenario
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
Allergan Plc
AstraZeneca Plc
Celgene Corp.
Johnson & Johnson Services Inc.
Takeda Pharmaceutical Co. Ltd.
PART 14: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Combination therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Combination therapy - Year-over-year growth 2019-2023 (%)
Exhibit 22: Monotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Monotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Proportion of geriatric population in Asia 2007 and 2017
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Pipeline molecules
Exhibit 44: Growth in geriatric population 2013-2017 (%)
Exhibit 45: Side effects of drugs treating mantle cell lymphoma
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Drug designations
Exhibit 48: Recently approved drug designations to drug candidates aimed to treat mantle cell lymphoma
Exhibit 49: Vendor landscape
Exhibit 50: Landscape disruption
Exhibit 51: Vendors covered
Exhibit 52: Vendor classification
Exhibit 53: Market positioning of vendors
Exhibit 54: Allergan Plc - Vendor overview
Exhibit 55: Allergan Plc - Business segments
Exhibit 56: Allergan Plc - Organizational developments
Exhibit 57: Allergan Plc - Geographic focus
Exhibit 58: Allergan Plc - Segment focus
Exhibit 59: Allergan Plc - Key offerings
Exhibit 60: Allergan Plc - Key customers
Exhibit 61: AstraZeneca Plc - Vendor overview
Exhibit 62: AstraZeneca Plc - Product segments
Exhibit 63: AstraZeneca Plc - Organizational developments
Exhibit 64: AstraZeneca Plc - Geographic focus
Exhibit 65: AstraZeneca Plc - Key offerings
Exhibit 66: AstraZeneca Plc - Key customers
Exhibit 67: Celgene Corp. - Vendor overview
Exhibit 68: Celgene Corp. - Business segments
Exhibit 69: Celgene Corp. - Organizational developments
Exhibit 70: Celgene Corp. - Geographic focus
Exhibit 71: Celgene Corp. - Key offerings
Exhibit 72: Celgene Corp. - Key customers
Exhibit 73: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 74: Johnson & Johnson Services, Inc. - Business segments
Exhibit 75: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 76: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 77: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 78: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 79: Johnson & Johnson Services, Inc. - Key customers
Exhibit 80: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 81: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 82: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 83: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 84: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 85: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 86: Validation techniques employed for market sizing
Exhibit 87: Definition of market positioning of vendors